gms | German Medical Science

27. Deutscher Krebskongress

Deutsche Krebsgesellschaft e. V.

22. - 26.03.2006, Berlin

Urogenital Tract Cancer including Prostate Cancer

Meeting Abstract (OP281)

Visible Quality - Benchmarking in Prostate Cancer Therapy

Schostak M, Schrader M, Albers P, Beer M, Althaus P, Diederichs W, Siegsmund M, Fabricius G, Hinkelbein W, Miller K, Projektgruppe Prostatakarzinom
Meeting Abstract (OP282)

PET/CT-Diagnostik zur Detektion des isolierten Lokalrezidivs bei Patienten nach Primärtherapie eines Prostatakarzinoms

Blumstein NM, Buck AK, Gottfried HW, Messer PM, Perner S, Röttinger E, Hautmann R, Reske SN
Meeting Abstract (OP283)

Prognostic risk factors for survival following adjuvant chemotherapy for locally advanced urothelial bladder cancer

Heidenreich A, Ohlmann C, Weidemann C, Engelmann UH
Meeting Abstract (OP284)

Organ preserving surgery in testicular cancer – longterm results of the German Testicular Cancer Study Group

Heidenreich A, Albers P, Kliesch S, German Testicular Cancer Study Group
Meeting Abstract (OP285)

Prolongation of progression-free and overall survival following an adjuvant vaccination with Reniale® in patients with non-metastatic renal cell carcinoma: Secondary analysis of a multicenter phase-III trial

Doehn C, Richter A, Theodor RA, Lehmacher W, Jocham D
Meeting Abstract (OP286)

Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)

Staehler M, Escudier B, Szczylik C, Eisen T, Oudard S, Stadler WM, Schwartz B, Shan M, Bukowski RM, BAY 43–9006 TARGETs Clinical Trial Group
Meeting Abstract (OP287)

Prognostic relevance of Rac GTPase protein overexpression in prostate carcinomas

Engers R, Walter A, Müller M, Ziegler S, Willers R, Gabbert HE
Meeting Abstract (OP288)

Comparative Gene Expression Analysis of PCa and HRPC samples

Werther M, Stoss O, Albers P, Middel P, Henkel T, Rüschoff J
Meeting Abstract (OP289)

Value of cellular fibronectin plasma levels as a marker in localized and metastatic renal cell carcinoma

Hegele A, Olbert P, Kosche B, Varga Z, Hofmann R, Kropf J
Meeting Abstract (OP290)

Risikoorientierte Hodentumor-Nachsorge zur Erfassung der Spätrezidive

Nabavi R, Weißbach L
Meeting Abstract (OP291)

Second-line chemotherapy with docetaxel for prostate-specific antigen (PSA) relapse in men with hormone-refractory prostate cancer (HRPCA) previously treated with docetaxel-based chemotherapy

Ohlmann C, Özgür E, Wille S, Engelmann UH, Heidenreich A
Meeting Abstract (PO292)

Tomato consumption and prostate cancer risk in EPIC-Heidelberg

Stiehm M, Nagel G, Linseisen J
Meeting Abstract (PO293)

RAR-beta1 overexpression in chromophobe renal cell carcinoma: a novel target for therapeutic intervention?

Schrader AJ, Goelden U, Pfoertner S, Olbert P, Hegele A, Elert A, Hofmann R
Meeting Abstract (PO294)

Follow-up strategies after paraaortic (PA) radiotherapy for stage I seminoma: What should we do and when should we do it?

Claßen J, Souchon R, Lächelt S, Hartmann JT, Hehr T, Bamberg M
Meeting Abstract (PO295)

Clinical outcome of patients with metastatic papillary renal cell carcinoma

Steiner T, Roigas J, Kirchner H, Doehn C, Heynemann H, Varga Z, Rohde D, Siebels M, Schubert J, Loening S, Jocham D, Fornara P, Hofmann R, Stief C
Meeting Abstract (PO296)

The risk of lymph node metastasis in patients with low risk prostate cancer undergoing radical prostatectomy

Heidenreich A, Ohlmann C, Engelmann UH, Schumacher M, Studer UE
Meeting Abstract (PO297)

Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormon-refractory prostate cancer (HRPC)

Nelius T, Klatte T, Reiher F, Lindenmeir T, Yap R, Allhoff EP
Meeting Abstract (PO298)

Functional and oncological outcome of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy

Heidenreich A, Ohlmann C, Wille S, Özgür E, Engelmann UH
Meeting Abstract (PO299)

Extended retropubic radical prostatectomy in clinically stage T3 prostate cancer (PCA) – significant reduction of positive surgical margins in a case control study

Heidenreich A, Ohlmann C, Wille S, Özgür E, Engelmann UH
Meeting Abstract (PO300)

Clinical Significance of a PSA Flare Phenomenon in Patients with Hormone Refractory Prostate Cancer receiving Docetaxel

Olbert P, Hegele A, Heidenreich A, Ohlmann C, Schrader AJ, Hofmann R
Meeting Abstract (PO301)

Morbidity after Transperineal Permanent Interstitial Seedimplantation (TPSI) in 334 Patient with "Low Risk“ Prostate Cancer

Block T, Zimmermann F, Czempiel H
Meeting Abstract (PO302)

Late side-effects in patients with conformal radiation therapy (CRT) for prostate cancer

Geinitz H, Zimmermann F, Thamm R, Müller T, Jess K, Erber C, Busch R, Molls M
Meeting Abstract (PO303)

Long-term health-related quality of life in men treated with 125I prostate brachytherapy for clinically localized prostate cancer

Schäfer J, Welzel G, Trojan L, Harrer K, Eppler N, Alken P, Wenz F
Meeting Abstract (PO304)

Molecular triggered therapy in hormone-refractory prostate cancer

Ohlmann C, Özgür E, Wille S, Engelmann UH, Dienes P, Heidenreich A
Meeting Abstract (PO305)

Ketokonazol/hydrocortisone versus estramustinphosphate in the management of PSA progression following primary androgen deprivation for metastatic prostate cancer

Ohlmann C, Cordia I, Engelmann UH, Heidenreich A
Meeting Abstract (PO306)

Disturbance of apoptosis regulators during tumour progression in renal cell carcinomas

Ramp U, Heikaus S, Yan Y, Mahotka C, Gabbert HE
Meeting Abstract (PO307)

The effect of image guided radiotherapy with stereotactic ultrasound on effectivity and late rectal toxicity in radiotherapy of prostate cancer

Mai SK, Bohrer M, Wertz HJ, Lohr F, Wenz F
Meeting Abstract (PO308)

Cultural Differences Among Hebrew or Arabic as a Mirror for Intercultural Differences

Weissenberger C, Hanin M, Schulze-Seemann W, Henne K
Meeting Abstract (PO309)

Immunotherapy of patients with hormone refractory prostate carcinoma treated with Interferon-gamma and autologous PSA-peptide loaded dendritic cells – A pilot study

Hildenbrand B, Sauer B, Langenkamp A, Stoll C, Kalis O, Freudenberg M, Galanos C, Niedermann G, Häring B, Leo R, Unger C, Azemar M
Meeting Abstract (PO310)

Biochemical recurrence (bREC) and survival in patients with conformal radiation therapy (CRT) for prostate cancer

Geinitz H, Zimmermann F, Thamm R, Müller T, Jess K, Erber C, Busch R, Molls M
Meeting Abstract (PO311)

The ING tumor suppressor genes and their specific role in the pathogenesis of renal cell carcinoma

Nichiporuk E, Gasser M, Hillig F, Lebedeva T, Lutz J, Grimm M, Najafian N, Kneitz B, Thiede A, Heemann U, Riedmiller H, Waaga-Gasser AM
Meeting Abstract (PE312)

Feasibility of adjuvant chemo-hormonal-bisphosphonate therapy in patients with high-risk prostate cancer following radical prostatectomy

Ohlmann C, Damm J, Özgür E, Engelmann UH, Heidenreich A
Meeting Abstract (PE313)

Expression analysis of 41 genes identifies a number of novel prognostic markers in Wilms tumors

Wittmann S, Zirn B, Klamt B, Graf N, Gessler M
Meeting Abstract (PE314)

Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer

Hegele A, Wahl HG, Varga Z, Sevinc S, Lisetta K, Schrader AJ, Hofmann R, Olbert P
Meeting Abstract (PE315)

Course and prognosis in Carcinomas of the Penis in Thuringia

Götze R, Göbel H, Strecker P, Altendorf-Hofmann A, Burger U, Fernschild K, Wackes M, Götze R
Meeting Abstract (PE316)

Outcome of radical prostectomy in patients with prostate cancer and preoperative Gleason score ≥ 8

Ohlmann C, Özgür E, Wille S, Engelmann U, Heidenreich A
Meeting Abstract (PE317)

A BCL-2-antagonist is able to activate the impaired mitochondrial apoptosis-pathway in renal cell carcinomas

Heikaus S, Mahotka C, Gabbert HE, Ramp U
Meeting Abstract (PE318)

Efficacy and safety of loading-dose ibandronate for rapid pain relief in patients with metastatic urologic cancer

Heidenreich A, Ohlmann C, Engelmann UH
Meeting Abstract (PE319)

Epithelial cell adhesion molecule (EpCAM) – a potential therapeutic target in prostate cancer (PCA)

Heidenreich A, Ohlmann C, Engelmann UH, Moll R, Rößler S, Konrad L, Bäuerle PA, da Silva A
Meeting Abstract (PE320)

RT-PCR for PSA mRNA improves the detection of metastases in pelvic lymph nodes of prostate cancer patients

Krause H, Schostak M, Schrader M, Miller K
Meeting Abstract (PE321)

Temozolomide in the management of progressive metastatic renal cell cancer (RCC) following immunotherapy

Pfister D, Ohlmann C, Damm J, Engelmann UH, Heidenreich A
Meeting Abstract (PE322)

Intravesically applied immunostimulatory DNA (CpG-ODN) reduces tumor load in an orthotopic murine transitional cell carcinoma (TCC) model (MB-49/ C57-Bl6)

Olbert P, Schrader AJ, Barth P, Hofmann R, Hegele A
Meeting Abstract (PE323)

Prostate cancer specific symptoms in a German reference population

Bestmann B, Loetters C, Weidner W, Küchler T, Rohde V
Meeting Abstract (PE324)

Quality of life after permanent brachytherapy in low-risk prostate cancer: prospective evaluation using EORTC QLQ-C30 and PR25 modules

Vordermark D, Noe M, Markert K, Baier K, Wulf J, Pohl F, Bratengeier K, Schön G, Flentje M
Meeting Abstract (PE325)

Transperineal Permanent Seed Implantation of “Low Risk” Prostate Cancer: 5 Years Experiences in 112 Patients

Block T, Zimmermann F, Czempiel H
Meeting Abstract (PE326)

Prognostic factors for the recurrence of renal cell carcinoma after radical nephrectomy

Sahi D, Ohlmann C, Schneider T, Engelmann UH, Heidenreich A
Meeting Abstract (PE327)

Down-regulation of DICE1 in prostate cancer cells by promoter CpG hypermethylation

Röpke A, Wieland I, Wieacker PF
Meeting Abstract (PE328)

Urine markers as possible tools for prostate cancer screening: a review focusing on performance characteristics and practicalness

Müller H, Brenner H
Meeting Abstract (PE329)

Selenium as an active agent in prevention and supportive therapy of prostate cancer: review of evidence

Theobald S, Russmann D
Meeting Abstract (PE330)

Is gemcitabine based chemotherapy feasible in elderly patients with advanced bladder cancer without any problems? - Investigations about the influence of age and comorbidity on therapy caused morbidity and mortality in elderly patients with gemcitabine based chemotherapy

Elert A, Schrader AJ, Heidenreich A, Hofmann R
Meeting Abstract (PE331)

Intensity modulated radiotherapy (IMRT) for high risk prostate cancer based on sentinel node optimized target volume definition

Ganswindt U, Paulsen F, Glocker S, Alber M, Corvin S, Hundt I, Bamberg M, Belka C
Meeting Abstract (PE332)

Epidemiological and clinical trends of Prostate Cancer in the region of the Regional Cancer Centre Dresden – an eight-years-analysis (1996–2003)

Böhm WD, Werner C, Strelocke K, Kunath H
Meeting Abstract (PE333)

Quality assurance through documentation – Oncological quality management in testicular cancer care

Popken G, Nitzke T, Wachter U, Schrader M, Miller K, Vogler H, Siegsmund M, Höppner D, Projektgruppe Hodentumor
Meeting Abstract (PE334)

Multimodal management of metastatic adrenocortical carcinoma – report of a rare case

Schwarte S, Brabant EG, Bastian L, Bruns F
Meeting Abstract (PE335)

The EU-ARCCS Study: An Open-Label, Non-Comparative, Phase-III Study of the Raf-Kinase Inhibitor Sorafenib as a Subsequent to First-Line Therapy in Patients with Advanced RenalCellCarcinoma

Beck J, Scheuring UJ, Mersmann S, Burk K, Huber C
Meeting Abstract (PE336)

Guideline implementation by second opinion centers – a new approach to better oncological care exemplified by germ cell tumors

Schrader M, Weissbach L, Hartmann M, Miller K, Krege S